# OnCo record belantamab-mafodotin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/belantamab-mafodotin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "belantamab-mafodotin" ;
  schema:name "Belantamab mafodotin"@en ;
  schema:description "A myeloma ADC that was withdrawn in 2022 then came back in 2025 after strong trials in earlier lines."@en ;
  schema:url <https://onco.cc/drugs/belantamab-mafodotin/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Belantamab_mafodotin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q98139657> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Belantamab%20mafodotin> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Blenrep" ;
  onco:approval "US 2020: Relapsed myeloma ≥4 lines (accelerated; withdrawn 2022)", "US 2025: Relapsed/refractory myeloma after ≥1 prior line, in combination", "EU 2025: R/R myeloma with BorDex or PomDex; 23 Jul 2025" ;
  onco:acceleratedApproval "US 2020-08-05: Adults patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/bcma/> ;
  onco:companies <https://onco.cc/companies/gsk/> ;
  onco:terms <https://onco.cc/terms/mc-non-cleavable/> ;
  onco:trials <https://onco.cc/trials/nct06868654/>, <https://onco.cc/trials/nct06956170/>, <https://onco.cc/trials/nct04162210/>, <https://onco.cc/trials/nct06679101/>, <https://onco.cc/trials/nct06868667/>, <https://onco.cc/trials/nct07084896/>, <https://onco.cc/trials/nct07150091/>, <https://onco.cc/trials/nct07227311/>, <https://onco.cc/trials/nct07217184/>, <https://onco.cc/trials/nct05714839/>, <https://onco.cc/trials/nct07150104/> .